Dan Maziasz is the Chief Business Officer at Kyverna Therapeutics, and is responsible for leading Kyverna’s corporate strategy, business development, alliance management, and commercial activities. Dan brings more than 25 years of corporate strategy and development experience from some of the industry’s top biopharmaceutical companies.

Prior to joining Kyverna, Dan served as Chief Business Officer at Atara Biotherapeutics, the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. At Atara, Dan led various corporate initiatives including strategic planning, licensing transactions with industry partners, and research collaborations with academic groups. Before his time at Atara, Dan was Vice President, Corporate Strategy and Business Development at Kite Pharma, a global cell therapy leader, prior to its acquisition by Gilead Sciences. Dan also spent more than a decade at Amgen, where he held roles of increasing responsibility in the US, Europe, and Asia across business development, corporate strategy, finance, and commercial functions. Dan began his career as a management consultant by advising large and small companies across healthcare, financial services, and other industries.

Dan received a B.S. in Business Administration and Economics from Saint Mary’s College of California and a M.B.A. degree from Loyola Marymount University.